Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Summary: EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have achieved clinical success in lung adenocarcinoma (LUAD). However, tumors often show profound but transient initial response and then gain resistance. We identify transcription factor ZNF263 as being significantly decreased in osimer...

Descripción completa

Detalles Bibliográficos

Autores principales:	Jiaqi Liang, Guoshu Bi, Qihai Sui, Guangyin Zhao, Huan Zhang, Yunyi Bian, Zhencong Chen, Yiwei Huang, Junjie Xi, Yu Shi, Qun Wang, Cheng Zhan
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2024-02-01
Colección:	Cell Reports
Materias:	CP: Cancer
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2211124724000998
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!